NCI to Fund Biomarker Studies for Hematopoietic Malignancies | GenomeWeb

NEW YORK (GenomeWeb News) – The National Cancer Institute plans to fund research that will use a range of 'omics technologies to develop and validate biomarkers for malignancies of the blood under two new grant programs.

NCI will use five-year R01 and two-year R21 grant mechanisms to support scientists developing genomic, proteomic, epigenomic, and transcriptomic delivery and development methods, as well as the use of standardized biospecimens for validation studies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.